Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
Results from the CARMENA trial, presented at the 2019 annual meeting of the American Society of Clinical Oncology suggest that cytoreductive nephrectomy should no longer be considered the…
Findings from a planned sub-analysis of clinical trial data comparing treatment options for renal cell carcinoma patients (RCC) with sacromatoid history were presented at the 2019 American Society…
A pilot study showing improved outcomes for metastatic renal cell carcinoma (mRCC) patients who were treated with immune checkpoint therapy after surgery, as compared with just immune checkpoint…
Recurrence after metastasectomy is common for patients with metastatic renal cell carcinoma (mRCC). In this study, treating with pazopanib after metastasectomy was shown to offer no additional survival…
